Moderna, Inc. Files SEC Form 4 Document: Insights into Equity Securities and Beneficial Ownership

Strategic Insights -

Moderna, Inc., a biotechnology company, has filed a document with the U.S. Securities and Exchange Commission (SEC) detailing its equity securities and beneficial ownership. The filing, made on November 4, 2022, provides insight into the company's ownership structure and transactions involving its directors, officers, and major shareholders. As a publicly traded company, Moderna's SEC filing is a formal document submitted to the commission.

Key Takeaways:

  • The filing is on Form 4, which reports changes in beneficial ownership of equity securities by directors, officers, and 10% owners.
  • The report includes information on the reporting person's relationship to Moderna, Inc., and transactions involving purchases and sales of equity securities.
  • The document contains a statement of ownership regarding equity securities registered under Section 12 of the Securities Exchange Act of 1934.
  • The SEC filing is a requirement for publicly traded companies to disclose changes in beneficial ownership of their equity securities.
  • The form requires reporting individuals to disclose their relationship to the company and any transactions involving the purchase or sale of equity securities.

Statistics:

  • The SIC code for Moderna, Inc. is 2836, Biological Products, (No Diagnostic Substances).
  • The company's SEC file number is 0001127602-22-024965.
  • The contact information for Moderna, Inc. is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139, 6177146500.
  • The initial filing is on Form 3, and changes are reported on Form 4.
  • The Annual Statement of beneficial ownership of securities is on Form 5.

Sources:

  • NewsRx, "U.S. Securities and Exchange Commission filing by Moderna, Inc. (Form 4)," November 4, 2022.
  • U.S. Securities and Exchange Commission, "Form 4: Statement of Changes in Beneficial Ownership," Moderna, Inc. (0001127602-22-024965).